Stockscreener 앱 받기
5.58
3.53%
0.19
시간 외 거래:
5.58
Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스
Insiders hold 63% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently - Yahoo Finance
(NVCT) Long Term Investment Analysis - Stock Traders Daily
Great week for Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders who have 63% stake and they haven’t stopped buying - Simply Wall St
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Acquires 4,500 Shares - MarketBeat
Nuvectis Pharma CEO Ron Bentsur buys $20,925 in shares By Investing.com - Investing.com Australia
Nuvectis Pharma CEO Ron Bentsur buys $20,925 in shares - Investing.com
Nuvectis Pharma stock hits 52-week low at $4.44 amid market challenges - Investing.com Australia
Marlio Charles Mosseri Purchases 17,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock - MarketBeat
Nuvectis pharma investor Mosseri-Marlio purchases $79,900 in shares By Investing.com - Investing.com
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium - The Manila Times
NVCT Stock Hits 52-Week Low at $4.61 Amid Market Challenges - Investing.com
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - MSN
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges - Investing.com Australia
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges By Investing.com - Investing.com South Africa
Nuvectis sinks after early-stage data for ovarian cancer therapy - MSN
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock By Investing.com - Investing.com Australia
Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma - Simply Wall St
Insider Buying: Nuvectis Pharma Inc (NVCT) Chairman & CEO Acquires Shares - GuruFocus.com
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock - Investing.com
Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 Shares - MarketBeat
Nuvectis pharma chairman buys $98,400 in common stock By Investing.com - Investing.com Canada
Nuvectis pharma chairman buys $98,400 in common stock - Investing.com
Nuvectis Pharma reports data from Phase 1b study of NXP800 - Yahoo Finance
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort - The Globe and Mail
500: Something went wrong - Investing.com Canada
Why Is Nuvectis Pharma Stock Trading Lower On Thursday?Nuvectis Pharma (NASDAQ:NVCT) - Benzinga
NVCT stock touches 52-week low at $5.05 amid market fluctuations - Investing.com India
U.S. Stock market: Nuvectis Pharma declined by 40.58% while Sow Good was down by 55.30% during mid day trading - Business Upturn
Nuvectis stock sinks on data for cancer drug (NVCT:NASDAQ) - Seeking Alpha
Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study - MarketWatch
Nuvectis Pharma Inc trading resumes - TipRanks
U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn
Nuvectis Pharma Reports Encouraging NXP800 Interim Data - GlobeNewswire
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase - The Bakersfield Californian
Nuvectis Pharma's NXP800 Shows Promise in Phase 1b Cancer Trial, New Dosing Success | NVCT Stock News - StockTitan
Trading (NVCT) With Integrated Risk Controls - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Announces Third Quarter 2024 Financial Results and Business Updates - Defense World
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Nuvectis Pharma's VP Michael Carson sells $22.5k in stock - Investing.com
Nuvectis Pharma's VP Michael Carson sells $22.5k in stock By Investing.com - Investing.com UK
FY2024 EPS Estimates for Nuvectis Pharma Raised by Analyst - Defense World
0.60%
2.24%
자본화:
|
볼륨(24시간):